IBSA Pharma and CUTISS complete license agreement for VitiCell
PRESS RELEASE Two innovative biotechnology specialists, IBSA Pharma and CUTISS complete license agreement for VitiCell® Agreement grants CUTISS exclusive worldwide license to commercialize VitiCell®. VitiCell® is a CE marked medical device developed by IBSA for the treatment of skin pigmentation disorders. Strategic fit with CUTISS’s expertise in skin tissue bioengineering. Sophia-Antipolis (France) and Zurich (Switzerland), 2 …
IBSA Pharma and CUTISS complete license agreement for VitiCell Read More »
